| scholarly article | Q13442814 |
| P2093 | author name string | Webberley MJ | |
| Melikian V | |||
| Hart MT | |||
| P2860 | cites work | Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study | Q28218032 |
| Verotoxin and neuraminidase induced platelet aggregating activity in plasma: their possible role in the pathogenesis of the haemolytic uraemic syndrome | Q33442517 | ||
| Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction | Q34043306 | ||
| Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces | Q34391659 | ||
| Raised plasma concentrations of platelet factor 4 (PF4) in Crohn's disease. | Q34526787 | ||
| Human platelet aggregation is initiated by peripheral blood mononuclear cells exposed to bacterial lipopolysaccharide in vitro | Q34545184 | ||
| THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS. III. COMPLICATIONS | Q35002356 | ||
| No evidence for a prethrombotic state in stable chronic inflammatory bowel disease | Q37177241 | ||
| Coagulation studies in ulcerative colitis and Crohn's disease | Q43771290 | ||
| Platelet size and age determine platelet function independently. | Q47238732 | ||
| Gel filtration. A new technique for separation of blood platelets from plasma | Q47658132 | ||
| The George E. Brown Memorial Lecture; current status of the problem of thrombosis | Q48565337 | ||
| Spontaneous platelet aggregation in cerebrovascular disease | Q50898121 | ||
| Cortisone in ulcerative colitis; final report on a therapeutic trial. | Q55499879 | ||
| Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal | Q59065336 | ||
| The role of platelets in myocardial infarction, ischemic heart disease, cerebrovascular disease, thromboembolic disorders and acute idiopathic pericarditis | Q67024912 | ||
| Platelets and diabetes mellitus | Q67700746 | ||
| Activation of blood coagulation in Crohn's disease. Increased plasma fibrinopeptide A levels and enhanced generation of monocyte tissue factor activity | Q69691382 | ||
| Intrahepatic kinetics of indium-111-labelled platelets | Q69980147 | ||
| Treatment of ulcerative colitis by the direct administration of an antifibrinolytic agent as an enema | Q70246992 | ||
| Cerebrovascular Occlusions in Relatively Young Patients With Regional Enteritis | Q70569038 | ||
| Studies on blood coagulation in ulcerative colitis and Crohn's disease | Q70709423 | ||
| Fibrinolytic Activity in the Normal and Inflamed Rectal Mucosa | Q71119909 | ||
| Indium (111In)-labelled human platelets: optimal method | Q71156767 | ||
| Hypercoagulability associated with chronic ulcerative colitis: changes in blood coagulation factors | Q72022824 | ||
| COMPARISON OF CLINICAL FINDINGS AND HEMATOLOGIC CHANGES IN PATIENTS WITH CHRONIC ULCERATIVE COLITIS | Q76668020 | ||
| THROMBOEMBOLIC PHENOMENA IN ULCERATIVE COLITIS. TWO CASE REPORTS | Q76721826 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammation | Q101991 |
| thromboembolism | Q891391 | ||
| inflammatory bowel diseases | Q917447 | ||
| P304 | page(s) | 247-251 | |
| P577 | publication date | 1993-02-01 | |
| P1433 | published in | Gut | Q5621669 |
| P1476 | title | Thromboembolism in inflammatory bowel disease: role of platelets | |
| P478 | volume | 34 |
| Q36474332 | Abnormal function of platelets and role of angelica sinensis in patients with ulcerative colitis |
| Q47944725 | Activated protein C resistance, thrombophilia, and inflammatory bowel disease |
| Q73941498 | Activation of plasma contact and coagulation systems and neutrophils in the active phase of ulcerative colitis |
| Q72655678 | Altered expression of cell adhesion molecules in uninvolved gut in inflammatory bowel disease |
| Q38645814 | An unusual cutaneous manifestation of ulcerative colitis: thrombotic skin gangrene |
| Q61892603 | Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease |
| Q41519637 | Antiendothelial cell antibodies (AECA) in patients with uveoretinitis |
| Q39147349 | Antiphospholipid Antibodies and Procoagulant Profile in Tunisians With Inflammatory Bowel Diseases. |
| Q71940048 | Antiphospholipid antibodies in inflammatory bowel disease |
| Q37243603 | Assessment of thrombophilic abnormalities during the active state of inflammatory bowel disease |
| Q39904967 | Biological markers in inflammatory bowel disease: practical consideration for clinicians. |
| Q48216497 | Budd-Chiari syndrome: a rare and life-threatening complication of Crohn's disease |
| Q45868602 | Can incoagulable blood protect against inflammatory bowel disease? |
| Q39939305 | Cerebral thromboembolic events in pediatric patients with inflammatory bowel disease |
| Q43151831 | Clubbing in Crohn's disease |
| Q41382149 | Coagulation parameters in inflammatory bowel disease |
| Q42065267 | Combined portal, splenic and mesenteric venous thrombosis in inactive ulcerative colitis with heterozygous mutation in MTHFR gene: A rare case of thrombophilia. |
| Q34099415 | Common carotid arterial thrombosis associated with ulcerative colitis |
| Q36076379 | Effects of dermatan sulfate derivatives on platelet surface P-selectin expression and protein C activity in blood of inflammatory bowel disease patients |
| Q38275040 | Epidemiology, risk factors and management of cardiovascular diseases in IBD. |
| Q42509215 | Evaluation of Erythrocytes, Platelets, and Serum Iron Profile in Dogs with Chronic Enteropathy |
| Q36470212 | Evaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease |
| Q47956330 | Evaluation of early atherosclerosis in patients with inflammatory bowel disease |
| Q45099627 | Formation of platelet-leukocyte aggregates in inflammatory bowel disease |
| Q34579752 | Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. |
| Q51550255 | Hyperhomocysteinemia in Greek patients with inflammatory bowel disease. |
| Q43669668 | Increased aggregation response of platelets in patients with inflammatory bowel disease |
| Q34570452 | Inflammatory bowel disease cause-specific mortality: a primer for clinicians |
| Q37437629 | Inflammatory bowel disease, such as Ulcerative colitis, is a risk factor for recurrent thromboembolic events: a case report |
| Q37270021 | Inflammatory bowel disease: a paradigm for the link between coagulation and inflammation |
| Q37454573 | Inflammatory bowel disease: epidemiology, pathology and risk factors for hypercoagulability |
| Q64886236 | Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. |
| Q36986500 | Interleukin-6 mediates the platelet abnormalities and thrombogenesis associated with experimental colitis |
| Q84135341 | Intima-media thickness of the common carotid artery is not significantly higher in Crohn's disease patients compared to healthy population |
| Q35596373 | Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? |
| Q71629579 | Is transdermal nicotine associated with cardiovascular risk? |
| Q27027022 | Laboratory markers in ulcerative colitis: Current insights and future advances |
| Q43734547 | Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease |
| Q21195814 | Mean platelet volume: a controversial marker of disease activity in Crohn’s disease |
| Q84997061 | Mesenteric vascular thromboembolism in inflammatory bowel disease: a single center experience |
| Q44461192 | Modulation of platelet aggregation responses by leukocytapheresis therapy in patients with active ulcerative colitis |
| Q33490306 | Myeloproliferative and metabolic causes |
| Q36171374 | Novel uses for anti-platelet agents as anti-inflammatory drugs. |
| Q38315631 | Overview of venous thrombosis in inflammatory bowel disease |
| Q73788274 | Persistence of hemostatic alterations in patients affected by Crohn's disease after bowel surgery |
| Q85384034 | Platelet Activation Markers Are Associated with Crohn's Disease Activity in Patients with Low C-Reactive Protein |
| Q30413361 | Platelet abnormalities during colonic inflammation |
| Q37625690 | Platelet activation and platelet-leukocyte aggregation elicited in experimental colitis are mediated by interleukin-6. |
| Q40612785 | Platelet dysfunction: a new dimension in inflammatory bowel disease |
| Q73351358 | Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients |
| Q40446257 | Portal vein thrombi after ileal pouch-anal anastomosis: its incidence and association with pouchitis |
| Q36727746 | Prognosis and management of Crohn's disease in the over-55 age group |
| Q41667925 | Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease |
| Q64057566 | Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension with active Crohn's disease |
| Q35133102 | Recurrent posterior strokes in inflammatory bowel disease patients |
| Q45876611 | Reduced free protein S levels in patients with inflammatory bowel disease: prevalence, clinical relevance, and role of anti-protein S antibodies |
| Q80430161 | Reticulated platelet levels in patients with ulcerative colitis |
| Q34078523 | Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease |
| Q34235823 | Review article: the management of severe Crohn's disease |
| Q41906609 | Skin gangrene as an extraintestinal manifestation of inflammatory bowel disease |
| Q36580179 | Stroke in inflammatory bowel disease: a report of two cases and review of the literature |
| Q38365449 | The relationship between coagulation state and inflammatory bowel disease: current understanding and clinical implications |
| Q43892147 | The utility of screening for asymptomatic lower extremity deep venous thrombosis during inflammatory bowel disease flares: a pilot study |
| Q47300421 | Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin. |
| Q38239252 | Thromboembolic complications in inflammatory bowel disease. |
| Q46784406 | Thromboembolic tendency (TE) in IBD (inflammatory bowel disease) patients |
| Q48241340 | Thromboembolism in active ulcerative colitis. |
| Q37477600 | Thrombophilic Risk Factors in Patients With Inflammatory Bowel Disease |
| Q36277417 | Thrombosis and inflammatory bowel disease |
| Q43064983 | Thrombosis and inflammatory bowel disease-the role of genetic risk factors |
| Q37789688 | Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention |
| Q44996420 | Thrombosis in inflammatory bowel disease: are we tailoring prophylaxis to those most at risk? |
| Q35368162 | Thrombosis in inflammatory bowel diseases: what's the link? |
| Q41126187 | Thrombotic occlusion of all left coronary branches in a young woman with severe ulcerative colitis |
| Q35586137 | Thromboxane synthase immunohistochemistry in inflammatory bowel disease |
| Q33348373 | Unusual manifestations of the antiphospholipid syndrome |
| Q48125001 | Upper limb DVT after an optical urethrotomy in a patient with a permanent pacemaker: a case for continuing anticoagulation during low-risk urological surgery |
| Q34714365 | Venous and arterial disease in inflammatory bowel disease |
| Q53088997 | Venous thromboembolism and underutilisation of anticoagulant thromboprophylaxis in hospitalised patients with inflammatory bowel disease. |
| Q33564092 | Venous thrombosis and prothrombotic factors in inflammatory bowel disease |
| Q54434317 | [Iron deficiency, thrombocytosis and thromboembolism]. |
Search more.